Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AU409 in Advanced Liver Cancers and Solid Tumors
NCT05791448Phase 1Suspended
- Sponsor
- University of Southern California
- Start
- Mar 2023
- Primary completion
- Mar 2027
- Modality
- Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AU-409 in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) and solid tumor, sponsored by University of Southern California. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase II Dose at 28 days and 1 more. Started Mar 2023; status: suspended.
02
Drugs
AU-409
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)solid tumor
Beyond the preview
Go deeper on NCT05791448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05791448.